Daniel Gladwell

The Cost Effectiveness of Licensed Oromucosal Midazolam (Buccolam®) for the Treatment of Children Experiencing Acute Epileptic Seizures: An Approach When Trial Evidence is Limited

Dawn Lee, Daniel Gladwell, A. Batty et al. · Pediatric Drugs · 2013 · 35 citations

Trial Evidence, Pediatric Neurosurgery, Oromucosal Midazolam +5

Cost Effectiveness of Renal Denervation Therapy for the Treatment of Resistant Hypertension in the UK

Daniel Gladwell, Mark Cook, Ron Akehurst · Applied Health Economics and Health Policy · 2014 · 24 citations

Hypertension, Urology, Resistant Hypertension +10

A comparison of the cost-effectiveness of treatment of prolonged acute convulsive epileptic seizures in children across Europe

Dawn Lee, Daniel Gladwell, Anthony J. Hatswell et al. · Health Economics Review · 2014 · 18 citations · Full text

Pharmacotherapy, Western Europe, Hospital Medicine +16

R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study

R. Hart, Darren Burns, Bram Ramaekers et al. · PharmacoEconomics · 2020 · 14 citations · Full text

Cost-effectiveness Analysis, Program Evaluation, Management +16

A cost–utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom

Dawn Lee, J. Porter, Daniel Gladwell et al. · Journal of Medical Economics · 2014 · 12 citations · Full text